Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)

Creative Commons License

Bonaca M. P., Nault P., Giugliano R. P., Keech A. C., Pineda A. L., Kanevsky E., ...More

CIRCULATION, vol.137, no.4, pp.338-350, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 137 Issue: 4
  • Publication Date: 2018
  • Doi Number: 10.1161/circulationaha.117.032235
  • Journal Name: CIRCULATION
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.338-350
  • Hacettepe University Affiliated: Yes

Abstract

Background: The PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor evolocumab reduced low-density lipoprotein cholesterol and cardiovascular events in the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). We investigated the efficacy and safety of evolocumab in patients with peripheral artery disease (PAD) as well as the effect on major adverse limb events.